DSM: Biofuels Digest’s 5-Minute Guide

Address:

Visiting:
Het Overloon 1
6411 TE Heerlen
THE NETHERLANDS

Mail:
A. Fleminglaan 1
2613 AX Delft
THE NETHERLANDS

Year Founded:
1902

Annual Revenues:
2009: 7,866 million EUR
2010: 9,050 million EUR
2011: 9,193 million EUR
2012 Jan-Jun 4,558 million EUR

Company description:
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 22,000 employees deliver annual net sales of about €9 billion.

DSM is a frontrunner in creating bio-based and environmentally sound solutions within its Bio-based Products and Services unit. DSM focuses on enabling technology in biofuels and bio-based chemicals and materials made from renewable biomass, and demonstrating the commercial viability of these technologies in collaboration with strategic partners along the value chain.

Major Investors
DSM is a publicly listed company at the NYSE Euronext Stock Exchange in Amsterdam,
The Netherlands (ticker symbol DSM KON).

3 Top Milestones for 2009-12

2009: as a partner in the KACELLE consortium led by DONG Energy, DSM received
a 1.1 M EUR grant from the European Commission (Framework Program 7) for the
development of advanced ethanol yeast. This yeast has the potential to improve the
economic viability of a wheat straw based biorefinery.
Reference: http://www.inbicon.com/Projects/KACELLE

2010: DSM announces breakthroughs in enzyme and advanced yeast technology for conversion of ligno-cellulosic feedstocks into ethanol.

2010: DSM and Roquette Frères announce joint venture agreement for the production, commercialization and market development of bio-based succinic acid.

2011: DSM strengthens its leadership position in advanced yeast and enzyme technologies for cellulosic biofuels by the acquisition of C5 Yeast Company from Royal Cosun, becoming the first industrial biotechnology company to offer both enzyme and yeast fermentation technologies.

3 Major Milestone Goals for 20

DSM

Unit: Bio-based Products & Services

 

Address:

Visiting:

Het Overloon 1

6411 TE Heerlen

THE NETHERLANDS

 

Mail:

A. Fleminglaan 1

2613 AX Delft

THE NETHERLANDS

 

Year Founded:

1902

 

Annual Revenues:

2009: 7,866 million EUR

2010: 9,050 million EUR

2011: 9,193 million EUR

2012 Jan-Jun 4,558 million EUR

 

Company description:

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 22,000 employees deliver annual net sales of about €9 billion.

DSM is a frontrunner in creating bio-based and environmentally sound solutions within its Bio-based Products and Services unit. DSM focuses on enabling technology in biofuels and bio-based chemicals and materials made from renewable biomass, and demonstrating the commercial viability of these technologies in collaboration with strategic partners along the value chain.

Major Investors

DSM is a publicly listed company at the NYSE Euronext Stock Exchange in Amsterdam,

The Netherlands (ticker symbol DSM KON).

 

3 Top Milestones for 2009-12

2009: as a partner in the KACELLE consortium led by DONG Energy, DSM received

a 1.1 M EUR grant from the European Commission (Framework Program 7) for the

development of advanced ethanol yeast. This yeast has the potential to improve the

economic viability of a wheat straw based biorefinery.

2010: DSM announces breakthroughs in enzyme and advanced yeast technology for conversion of ligno-cellulosic feedstocks into ethanol.

2010: DSM and Roquette Frères announce joint venture agreement for the production, commercialization and market development of bio-based succinic acid.

2011: DSM strengthens its leadership position in advanced yeast and enzyme technologies for cellulosic biofuels by the acquisition of C5 Yeast Company from Royal Cosun, becoming the first industrial biotechnology company to offer both enzyme and yeast fermentation technologies.

2012: Royal DSM, the global Life Sciences and Materials Sciences company, and POET, LLC, one of the world’s largest ethanol producers, join forces to commercially demonstrate and license cellulosic bio-ethanol.

 

Major Milestone Goals for 2013-15

2012 – Q4: technical completion & start up bio-succinic acid plant Reverdia in Cassano, Italy

2013: Start-up of Project Liberty, POET-DSM Advanced Biofuels’ plant in Emmetsburg, IA (U.S.A.)

2014: First sales of technology licenses by joint ventures POET-DSM Advanced Biofuels and Reverdia.

 

Business Model:

DSM focuses on enabling technology in biofuels and bio-based chemicals and materials made from renewable biomass, and demonstrating the commercial viability of these technologies in collaboration with strategic partners along the value chain.

Primarily, we see our future in the development and supply of high value knowledge, ingredients and expertise in the field of bio-conversion technology – licensed out to bio-based entrepreneurs, to access and convert biomass in the most commercial and sustainable ways possible, rather than as an owner/operator of manufacturing facilities.

Competitive Edge(s):

• DSM is the first to offer both enzyme and yeast solutions for ethanol production from ligno-cellulosic feedstock, with a >100 year track record in biotechnology and chemo-catalytic routes
• DSM is an early mover in this industry, prepared to take entrepreneurial risk
• DSM is focused on food/feed, as well as on fuel/energy/chemicals

 

Research, or Manufacturing Partnerships or Alliances.

With Roquette Frères (France) in JV Reverdia® for development and production of Succinic Acid, and licensing technology thereof

With POET(Sioux Falls, SD) in POET-DSM Advanced Biofuels for development and production of cellulosic ethanol, and licensing technology thereof

With BP Biofuels: partnership to develop process for ‘sugar to diesel’ conversion technology (fermentative route).

 

Stage  (Bench, pilot, demonstration, commercial)

All of the above

 

Company Website